Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
53.17
-2.96 (-5.27%)
At close: Nov 16, 2026, 4:00 PM EST
53.00
-0.17 (-0.32%)
Pre-market: Nov 17, 2026, 4:01 AM EST
← View all transcripts

UBS Global Biopharma Conference 2026

Nov 16, 2026

Summary

MYQORZO is gaining U.S. prescribing share, with MAPLE data added to its label and more than 80% of symptomatic, diagnosed oHCM patients still outside CMI therapy. Global launches, potential nHCM expansion and real-world evidence to support REMS changes are key growth priorities.

Ash Verma
Analyst, UBS

All right, great. Good day, everybody. Next session here at UBS Biopharma Conference is Cytokinetics. Very excited to have the whole team here. Just quickly, Robert, thank you so much for joining us. Fady, Andrew, and Sung, this is really amazing. Thanks for joining our conference. Maybe, Robert, if you can give us a brief outline of what are some of the highlights coming out of third quarter earnings. I think people know the story very well, but just if you can hit on some of the key points that you outline.

Robert Blum
President and CEO, Cytokinetics

Sure. Coming out of Q3 earnings, we feel like we're executing very, very well on our commercial launch of MYQORZO with focus to the U.S., but also with inclusion of Germany and soon other countries to follow. As it relates to the U.S., we believe we're delivering against all of the metrics and objectives, the KPIs that we laid out for the street earlier in the year. My colleagues can speak to them in detail. But as it relates to demonstrating that we are having effect to increase the prescribing of cardiac myosin inhibitors category growth at the same time we are climbing in preferential share of new scripts, we think we're demonstrating that MYQORZO, as differentiated, is meaningfully impacting the disease oHCM, but still with plenty of upside.

Even all together, BMS and Cytokinetics work now with CAMZYOS and MYQORZO respectively, we still have upwards of 80% of symptomatic diagnosed oHCM patients in the United States who are not receiving a cardiac myosin inhibitor. This morning, we announced that the U.S. FDA has approved our sNDA to be enabling of data from MAPLE-HCM to be included in an expanded label for MYQORZO. Why is that important? It's especially important because the bar was already very high. The data from SEQUOIA, the original pivotal study of MYQORZO, informed a label that included all patients with oHCM, with or without the beta blockers. One asks, why then submit the MAPLE data? FDA is now permitting of inclusion of MAPLE data as could be enabling of further differentiation for MYQORZO. MAPLE was a study of monotherapy aficamten versus monotherapy metoprolol.

Now we have in the label data to suggest why MYQORZO could be considered as an alternative to a beta blocker. Now, keep in mind, we believe, and as we've been guiding all along, we think this is incremental because the label already included all of oHCM. But for these data now in label, add to that our expectation that next year the guidelines may be updated to reflect MAPLE data and elevating aficamten in the step edit of patients around oHCM. We think this could be together transformative at that time. I think all of this combined underscores Cytokinetics is doing what it said it was going to do, executing well on the commercialization of MYQORZO, expanding the label to include MAPLE-HCM. Next up is, as we guided, submission of an sNDA inclusive of ACACIA data, and as that could be factoring into label next year.

So it is incumbent upon us to continue to pioneer and lead, and we think we are doing just that.

Ash Verma
Analyst, UBS

Great. Awesome. So yeah, thanks a lot for that, and yeah, and congrats on the first-line approval. Maybe I will start there. I think it is interesting that, so you mentioned that the guidelines could get updated next year, but the payers would still step edit through the beta blockers. I am surprised that there is so much resistance in the payer community. This is not a massive market, right? But when you think about that, the data that we have seen, beta blockers are actually hurting patients. So I have been just thinking, what is the argument that you hear from payers in terms of, let us say, not putting CMIs first line, for MYQORZO first line, given that we have seen such an amazing data, and if the guidelines also get updated, then what would be their response to not use it?

Robert Blum
President and CEO, Cytokinetics

Like with anything else, there is inertia.

Ash Verma
Analyst, UBS

Right.

Robert Blum
President and CEO, Cytokinetics

Inertia gets chipped away with more and more evidence, more and more time. So maybe Andrew could speak to payer feedback in connection with these matters, and then Fady could speak to physician behavior.

Andrew Callos
EVP and Chief Commercial Officer, Cytokinetics

Yeah. I mean, payers are certainly leading on guidelines as kind of their argument for why have utilization criteria around trying a beta blocker first, or a physician attesting that a beta blocker has been tried or the patient can't take it. Payers, this category and all categories, typically will put up challenges to make sure that appropriate patients are taking therapies that are more costly than what physicians have used historically. I think it's probably in our best interest for now to more accelerate the addition of a CMI, as compared to take on payer as a try for monotherapy. If we did that, I think there'd be a lot more contracting, rebating, market access would be more challenging than it is as a category.

I think as Robert said, inertia, data, over time, especially if nHCM is approved, that guidelines get updated, you may see criteria loosened, but not in the next one, two years.

Fady Malik
EVP of Research and Development, Cytokinetics

Yeah, I think to influence physician behavior, step one is to generate high-quality data. With MYQORZO, we now have SEQUOIA, we have MAPLE, we have ACACIA, FOREST data. The guidelines were written on expert opinion because there was no high-quality data for the use of beta blockers or everything else. That's not a position. I mean, they accommodate expert opinion because sometimes there's nothing else to fall back on, but the field is being transformed by now availability of high-quality, randomized controlled clinical data. They, I expect, will be updated to reflect that in the next version, which we expect in 2027. Guidelines then help influence physician behavior, because the guidelines are the ultimate kind of peer review, and your peers have now voted to position things a certain way. Physicians, I think they incorporate that into their practice as well.

Most of the truly expert physicians have moved, they're not waiting for the guidelines, they've already moved to implement—

Robert Blum
President and CEO, Cytokinetics

Yeah.

Fady Malik
EVP of Research and Development, Cytokinetics

—in their practice that the data that have been presented and published now.

Robert Blum
President and CEO, Cytokinetics

But I think the net of what you're hearing from Andrew and Fady is that payers will come along when they see physician behavior altering and the use of aficamten more frontline. In the meantime, physicians, knowing of this payer headwind, will likely be moving more swiftly through beta blockers, step edit through them more rapidly in order to be able to get their patients sooner on aficamten.

Ash Verma
Analyst, UBS

Right. Okay, perfect. And then maybe if we talk about the launch updates on oHCM. So you've noted 9,000 eligible patients in the CMI category, also seeing more than 3,000 adds per quarter. So pretty impressive metrics. Just like when you think about fourth quarter or next year, is this growth momentum going to continue? And how do you sort of sustain this growth into subsequent quarters?

Robert Blum
President and CEO, Cytokinetics

I'm going to answer your question, but I'm going to start a little farther back. So if you think about where we were this time a year ago, will MYQORZO get approved? If it gets approved, will it have a differentiated risk mitigation profile? And if launch, how are you going to compete with BMS? Think about where we are now. MYQORZO is approved. It has a differentiated label and , and REMS at the same time, we're demonstrating, even as audacious as we set goals to have a preferential share of new scripts within six to nine months, we're getting to a place where I think this is demonstrating to be a very strong commercial launch, and with plenty of upside still remaining in the market that is still not yet penetrated. So we set at the beginning of the year these KPIs.

I am going to ask Andrew to answer your question and where we are relative, but I think there is tremendous momentum building, tremendous momentum building for MYQORZO and the work that we are doing. As we, even as a small company working in a category that BMS has been in for four years, we are demonstrating that we are a leader.

Andrew Callos
EVP and Chief Commercial Officer, Cytokinetics

Yeah. Growth is really fueled by new prescribers. I think in the third quarter, on our earnings call, we highlighted that over 70% of the market growth is because of what were previously naive to CMI prescribers. When we sized our field force, we looked at those who treat and diagnose HCM. Obviously, before CMIs, that was largely with beta blockers. So we are targeting and, in the U.S., discussing MYQORZO with these 11,000 physicians. There are only around maybe 2,500 who prescribe today, and as that number grows, you are going to see the category grow as well, because there is a lot of patients in community that do not go to large centers, do not go to academic centers, but we are also seeing growth in the large academic centers. 30% of the growth was there as well. So, we are expecting the market to continue to grow.

MAPLE should accelerate some level of growth, especially in the community. ACACIA will be a much larger growth driver for the CMI category overall. If you think about the community that doubles on average the population size of patients, because it is a 50/50 O versus N split. The market, if you look at market nine months year- to- date this year versus last year, the market grew about 50% overall. Again, most of that is because of new prescribers. So continue to accelerate growth within the category of that concentration of high prescribers, but at the same time expand utilization. That is what we said even before our launch, what it is going to take for this category to be in the multi-billions that we know that it can be.

Ash Verma
Analyst, UBS

Yeah. Yeah, that is great. Okay. If you focus on some of the ex-U.S. launch updates, so you have seen a few approvals now, China, EU, U.K., Canada, just sort of early stage in these launches, but yeah, how do you expect the ramp to be for these categories?

Robert Blum
President and CEO, Cytokinetics

I do think that, putting it into context, the China business, the Europe business, they together are still not going to represent more than 10%-20% of the total U.S. business. With that caveat, we do think it's important to ensure that MYQORZO is made available to patients all over the world. It is available now in China, it is available in Germany, and in this quarter, launching in the U.K. Next year, we expect by the end of the year to be ensuring that MYQORZO is available throughout all of the major markets of Europe, and over time, even beyond the major markets. We do think that this is a global launch. We've taken on something that a lot of biotech companies in the U.S. are reluctant to do, which is go to market globally.

We think through our own actions and through that which our partners are doing, we're doing right by science, medicine, and patients to make MYQORZO available globally. In every country where we're operating, keeping in mind our fiduciary obligations and understandings of the economics, we expect we can build a profitable business in every country, even as there's pricing differential between countries. Andrew can speak to how we're doing, but in Germany, we're demonstrating that we can compete very effectively.

Andrew Callos
EVP and Chief Commercial Officer, Cytokinetics

Yeah. Germany is the market that has launched where we're commercializing, and Germany's already over 50% in new-to-brand share, just a few months into launch, and they've had three months in a row of that level of performance. Germany's doing extremely well in the market. As Robert said, the U.K. is launching this quarter, France in the first quarter. Germany and France are half of Europe overall in terms of value. We're expecting to have eight additional launches next year in Europe. Next year is a big year for Europe overall. It's equal in size to patient volume in the U.S., but because of the pricing difference, that's where we'll be 15% of our overall revenue a few years out when we start to get Europe growing on a country-by-country basis.

But we're very pleased with our European team, we're very pleased with our uptake, and we're continuing to see growth in each of these markets as our expectation.

Ash Verma
Analyst, UBS

Great. So maybe just switching gears to, I know there's been a lot of just investor discussion around the competitor updates that we've seen on the trial design, and this has taken a life of its own. So I'm really surprised how much your stock has traded around this. But it seems like, yeah, so this whole concept of that, okay, like now they've proposed three echoes, but not ready for titration. I want to hear your perspective, like what are investors missing on this? Because it seems like it is having an impact on your stock, but I'm curious to understand the differentiation that the competitor has proposed based on the trial design. Why is that or not a differentiation based on how you look at it?

Robert Blum
President and CEO, Cytokinetics

Sure. So there's a concept in science and research and development, signal to noise. I think there's a tremendous amount of noise around this space and theoretical differentiation that I think is not representative of signal. In time, signal rises above noise. What we're hearing from companies that purport to be followers is that through work that they're doing, they may be in a position to capture some of the white space around which MYQORZO in the marketplace may leave open opportunity. That would be potentially three, four, five years down the road, representative of an opportunity that somehow will escape us. I want to be clear, as the pioneer and leader, there's nothing that's been spoken that we're not already well intentional to executing to be enabling of Cytokinetics to continue to maintain its leadership.

Whether that's time to optimal dose, whether that's a differential number of echoes, and what that may mean for REMS, these are all things that with the combination of registries, physician-sponsored studies, phase IV studies that we may sponsor, real-world evidence, we're already demonstrating that we believe we'll be able to achieve. I'm going to ask each of Fady and Andrew to speak to this in the context of what are the prevailing doses of aficamten currently demonstrating leadership in this space, 5 mg, 10 mg primarily maintained, and how over time we may see an evolution of REMS and label for MYQORZO.

Andrew Callos
EVP and Chief Commercial Officer, Cytokinetics

Sure. So, just from a dosing point of view, we have over 1,000 patients who are on their maintenance dose. When we looked a few months ago at a data cut, 50% of those patients are on 5 mg on a maintenance dose, and 30% on 10 mg. So 80% are on 5 mg or 10 mg.

If a patient's on 5 mg , they start at 5 mg , they get an echo. If the echo is confirmatory that 5 mg is the right dose, they get an echo. Most, as long as their EF is over 55%, they're six months out. So you have two echoes in a single year for half of our patients that are on that 5 mg dose, and three echoes if you're on that 10 mg dose. I think we're seeing in the real world as well, we're not titrating every two weeks like we did in the clinical trial. We have a two to eight-week window that is a differentiator in terms of labeling, and generally, physicians are taking longer than four weeks with patients to titrate up.

So that's what we're seeing in the real world, and we're certainly going to discuss how we leverage and communicate that to physicians so they understand what we're seeing in terms of dosing. I don't know if that is—

Fady Malik
EVP of Research and Development, Cytokinetics

Yeah, I think the other concept is that physicians use echoes to help guide therapy because it's a measure of how effective therapy is. In the absence of measuring gradients, you can talk to patients. If any of you have done that, I did that for many years, it's very difficult to suss out of a patient exactly whether they're feeling better, they're not feeling better. You like objective data, and the echoes provide some objective data. What you want really is flexibility about using them, how to use them, when do you use them. As Andrew pointed out, physicians are using 5 mg and 10 mg. They're finding that their patients are, in many cases, feeling better, the numbers are getting better, and they are staying pat for a while. So, playing this forward three, four years from now, there'll be tens of thousands of patients on aficamten.

There will be tens of thousands of patient years of experience. The data supporting long-term effectiveness, effects on remodeling, all those kinds of things, they take time to generate, and that body of evidence will be established for aficamten. So I think there will remain a large differentiation between two medicines, even if all the unknowns about them in terms of safety profile, AFib profile, how will they ultimately be, and all of those things, even if they get the best-case scenario. As we see, we think aficamten is a highly effective medicine. It doesn't get 100% market share overnight. It takes time.

Robert Blum
President and CEO, Cytokinetics

The other thing I'll add is, if you've been a good student of this marketplace, you understand that a protocol is not a label. If you look at the EXPLORER study that MyoKardia conducted with mavacamten, the way they dosed mavacamten in that pivotal study is very dissimilar from the way ultimately FDA and the Division of Risk Management imposed a REMS. If you look at our study, we had no dose interruptions in SEQUOIA, but FDA still, after a while, decided it was necessary to have a REMS. It wasn't the cardiorenal division that decides that. It's the Division of Risk Management within FDA. I wouldn't over-interpret or extrapolate beyond information provided in the start of a phase III study for what that ultimately might look like in the way of a label.

I think precedent would suggest that any third or fourth entrant coming into a category is more likely to have a restrictive REMS than to have a less restrictive REMS. We believe very much so, and based on conversations with FDA and precedent, that the way to relax and remove a REMS is not through a phase III study, but through real-world evidence.

Ash Verma
Analyst, UBS

Yeah, and we've seen that Bristol did that, right, for CAMZYOS. I think some of the things that you're alluding to here, just that in real world, the data has been much better compared to the clinical trial on these 5 mg, 10 mg doses. I'm just curious to understand how long or what level of evidence would FDA need to look at to, let's say, supposedly relax the label criteria. Then, MYQORZO, I think from the time when they launched to when the label was updated, I think it was three and a half years, I believe.

Fady Malik
EVP of Research and Development, Cytokinetics

CAMZYOS, yeah.

Ash Verma
Analyst, UBS

So, CAMZYOS , sorry. So yeah, if you can just help us understand, I mean, you launched this year, is there any certain threshold, these many patients, or what do you need to show to approach the FDA with that?

Robert Blum
President and CEO, Cytokinetics

Before I ask Fady to comment, I might just say, it took BMS and with CAMZYOS three years to get a relaxation of the REMS, but also the adoption curve was different.

Fady Malik
EVP of Research and Development, Cytokinetics

Right.

Robert Blum
President and CEO, Cytokinetics

We already, this year, are demonstrating 3x-4x more patients on MYQORZO than were on CAMZYOS in its first six to nine months. With that said, it still takes thousands of patient years of experience, and then maybe Fady can speak to our strategy.

Fady Malik
EVP of Research and Development, Cytokinetics

Yeah, there's a big difference between a clinical trial that has 150 patients on drug for six months, that's 75 patient years, as opposed to 8,000-9,000, 10,000 patients on drug even for a year. Huge difference in the real world. And so those data, first of all, will inform safety profile quite more extensively than we even generate in our clinical trials. And we expect, from what we're seeing already in the REMS, an excellent safety profile, if anything, as good or better than we saw in our clinical trials, low burden on patients, safety. To be able to take those data to FDA, couple years timeframe, two and a half, it's hard to say. There's no specific. You just approach them when you think you're ready, and you kind of go from there.

Our goal is to ensure we have a very solid argument for thinking about how to peel back some of the requirements of the REMS. Not necessarily complete removal of it upfront, but there are different things we can do in stages to roll it back that I think will engage FDA constructively in that particular discussion.

Robert Blum
President and CEO, Cytokinetics

I encourage investors to go to school on precedents in this area where there were REMS and what it took to reduce or remove a REMS. We certainly are good students of that history, and we are applying it in the way we approach collection of real-world evidence with MYQORZO. One of the advantages of having a REMS is every one of those patients is tracked longitudinally, and those data get reviewed, analyzed, and submitted to FDA as part of an annual reporting process. We are on top of all of that.

Ash Verma
Analyst, UBS

Right. I will just ask if there is any question in the audience. I have a few after that. If not, then maybe. Just a quick clarification. Just by the nature of it, the echo that is done for titration, is that in any way different compared to the trial initiation echo and the end of trial? Is there a big difference? If you—

Fady Malik
EVP of Research and Development, Cytokinetics

Oh, very different, I think.

Ash Verma
Analyst, UBS

Okay.

Fady Malik
EVP of Research and Development, Cytokinetics

In just titrating the drugs, physicians are instructing their echo labs to just measure what we need to know.

Ash Verma
Analyst, UBS

Okay.

Fady Malik
EVP of Research and Development, Cytokinetics

An echo can measure 100 different things, but you only really need to know two things. They're what we call limited echoes. We had them in even SEQUOIA and ACACIA that during dose titration, we had a much shorter protocol for measurements we made, and then a more extensive protocol after dose titration was complete. There's a lot of efficiencies that are gained through experience.

Ash Verma
Analyst, UBS

Yeah, perfect. Let's talk about the non-obstructive side. You have this filing going in at certain point of time. Any label consideration or launch uptake dynamics that you want to call out, compared to oHCM, how it has played out?

Fady Malik
EVP of Research and Development, Cytokinetics

Well, we are on track to submit our supplemental NDA this quarter, as we guided to on our last earnings call. The review process will take place. We are very optimistic around as we look at support in the patient and physician community and their enthusiasm, strength of the data in ACACIA. When you look at the safety profile, we acknowledge it was different, but when you look at how aficamten was employed, while these patients moved into the open-label extension, even the ones that were drug-naive in ACACIA, the incidence of heart failure events was much lower. Again, we expect all of that. We've made that very clear and evident in the documents that we're submitting. The implementation of it in the REMS is likely within the same REMS.

It's a bit of a, you need to add a couple things here and there, not really additional complications. You need to train the physicians on the new indication, and those sorts of things. But if all goes well, then we'd expect an approval by hopefully this time next year, and then we'll turn it over to Andrew.

Robert Blum
President and CEO, Cytokinetics

Before we ask Andrew to comment, because he's engaged some key opinion leaders and others around market research for nHCM, I do think the street is underestimating the impact and the potential for MYQORZO in nHCM. If you go back to where we were and anticipating a potential approval in oHCM, quite a significant more refinement of models and analyst estimates and investor forecasting in and around oHCM. Seems to me that work is still to be done in nHCM, where we will be the only, if approved, cardiac myosin inhibitor that has approval across the full spectrum of HCM, inclusive of gradients, or not, obstructive or not. And that's where I believe there's tremendous upside that is potentially needing to be better acknowledged. Andrew, maybe you can comment on feedback you've received in and around the target product profile from aficamten in nHCM.

Andrew Callos
EVP and Chief Commercial Officer, Cytokinetics

Sure. So there is a good deal of excitement from physicians about having an option to treat patients. When we looked at those that are CMI-experienced physicians, many of them anecdotally have told us they have patients that they are waiting to treat if the product's approved. And then we're also expecting, based on what these physicians told us, an acceleration of launch for nHCM with that subset of experienced CMI physicians. The reaction has been quite positive on the overall profile of the medication. Obviously, there are those that are New York Heart Class II, III, those that are symptomatic, they're the ones that they'll focus on, which is not any different than oHCM.

Currently, we're updating our disease awareness campaigns to cover HCM overall, and we're doing market research around our campaign and how we will roll out nHCM, so we're ready if we get approved by this time next year.

Robert Blum
President and CEO, Cytokinetics

And maybe before we run out of time, I might just ask Sung to comment. Cytokinetics is a company that takes very seriously the way we access and deploy capital and the way we're managing to those sorts of economics and metrics that matter to shareholders, and maybe Sung can speak to that for the business.

Sung Lee
EVP and CFO, Cytokinetics

Sure, absolutely. So we'll continue to be very disciplined with our capital allocation. As you know, we maintain a very strong balance sheet, $1.6 billion at the end of the last quarter. This will come in very handy as we continue to launch MYQORZO in the U.S. But we have important launches in Europe, as Andrew and Robert mentioned earlier. But in addition to the commercial launches, it's very important that we maintain a robust pipeline. So, this is what we'll continue to be focused on with our capital allocation.

Robert Blum
President and CEO, Cytokinetics

And we are investing very, very substantially in advancing and augmenting pipeline, and I think in 2027, we'll have a lot more to say about that.

Ash Verma
Analyst, UBS

Perfect. With that, it's a wrap. So thank you so much, everybody, for joining, and looking forward to hearing more about the story.

Robert Blum
President and CEO, Cytokinetics

Thank you.

Fady Malik
EVP of Research and Development, Cytokinetics

Thank you.

Sung Lee
EVP and CFO, Cytokinetics

Thanks, Ash.